Marinus to present Ganaxolone DATA at American academy of neurology annual meeting
April 18, 2017 07:30 ET
|
Marinus Pharmaceuticals, Inc.
Platform Presentation of Phase 2 Data in Fragile X Syndrome RADNOR, Pa., April 18, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the...
Dr. Lorianne K. Masuoka Joins Marinus Pharmaceuticals as Chief Medical Officer
April 11, 2017 07:30 ET
|
Marinus Pharmaceuticals, Inc.
RADNOR, Pa., April 11, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and...
Ganaxolone IV Clinical Data Presented at Leading International Status Epilepticus Medical Conference
April 10, 2017 07:30 ET
|
Marinus Pharmaceuticals, Inc.
RADNOR, Pa., April 10, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and...
Marinus Pharmaceuticals to Present at Oppenheimer Healthcare Conference
March 15, 2017 07:30 ET
|
Marinus Pharmaceuticals, Inc.
RADNOR, Pa., March 15, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and...
Marinus Pharmaceuticals Provides Business Update and 2016 Financial Results
March 13, 2017 07:30 ET
|
Marinus Pharmaceuticals, Inc.
RADNOR, Pa., March 13, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and...
Ganaxolone Reduces Seizures and Improves Behaviors in Angelman Syndrome Preclinical Model
February 14, 2017 07:30 ET
|
Marinus Pharmaceuticals, Inc.
Data Published in NeuropharmacologyRADNOR, Pa., Feb. 14, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative...
Marinus Appoints Michael R. Dougherty to its Board of Directors
February 01, 2017 07:30 ET
|
Marinus Pharmaceuticals, Inc.
RADNOR, Pa., Feb. 01, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and...
Marinus Announces Positive Preliminary Data From Children With CDKL5 Genetic Disorder
January 23, 2017 07:30 ET
|
Marinus Pharmaceuticals, Inc.
Plans to Apply for Orphan Drug Designation RADNOR, Pa., Jan. 23, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), today announced positive preliminary data from the initial...
Marinus Provides Business Outlook for 2017
January 05, 2017 07:30 ET
|
Marinus Pharmaceuticals, Inc.
Several Data Milestones Anticipated With Ganaxolone RADNOR, Pa., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the...
Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone to Treat Fragile X Syndrome
January 03, 2017 07:30 ET
|
Marinus Pharmaceuticals, Inc.
RADNOR, Pa., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and...